keyword
MENU ▼
Read by QxMD icon Read
search

Castrate resistant prostate cancer

keyword
https://www.readbyqxmd.com/read/29792198/radioligand-therapy-of-metastatic-castration-resistant-prostate-cancer-current-approaches
#1
REVIEW
Zool Hilmi Awang, Markus Essler, Hojjat Ahmadzadehfar
Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target for diagnostic and therapy of prostate cancer and its metastases. This article discusses several articles on radionuclide treatments in prostate cancer and the results on PSMA therapy with either beta or alpha emitters as a salvage therapy...
May 23, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29790867/fluorine-18-fluorocholine-pet-ct-parameters-predictive-for-hematological-toxicity-to-radium-223-therapy-in-castrate-resistant-prostate-cancer-patients-with-bone-metastases-a-pilot-study
#2
Lavinia Vija Racaru, Mathieu Sinigaglia, Salim Kanoun, Fayçal Ben Bouallègue, Ilan Tal, Sévérine Brillouet, Mathilde Bauriaud-Mallet, Slimane Zerdoud, Lawrence Dierickx, Delphine Vallot, Olivier Caselles, Erwan Gabiache, Pierre Pascal, Frederic Courbon
PURPOSE: This study aims to predict hematological toxicity induced by Ra therapy. We investigated the value of metabolically active bone tumor volume (MBTV) and total bone lesion activity (TLA) calculated on pretreatment fluorine-18-fluorocholine (F-FCH) PET/CT in castrate-resistant prostate cancer (CRPC) patients with bone metastases treated with Ra radionuclide therapy. PATIENTS AND METHODS: F-FCH PET/CT imaging was performed in 15 patients with CRPC before treatment with Ra...
May 21, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29789876/-new-treatment-option-apalutamide-for-nonmetastatic-castration-resistant-prostate-cancer
#3
B Hadaschik, A Panic
No abstract text is available yet for this article.
May 22, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29787892/the-role-of-bisphosphonates-or-denosumab-in-light-of-the-availability-of-new-therapies-for-prostate-cancer
#4
REVIEW
Fred Saad, Cora N Sternberg, Peter F A Mulders, Daniela Niepel, Bertrand F Tombal
Most men with advanced prostate cancer will develop bone metastases, which have a substantial impact on quality of life. Bone metastases can lead to skeletal-related events (SREs), which place a burden on patients and healthcare systems. For men with castration-resistant prostate cancer (CRPC) and bone metastases, the treatment landscape has evolved rapidly over the past few years. The relatively recent approvals of the hormonal agents abiraterone acetate and enzalutamide, second-line chemotherapy cabazitaxel, and the radiopharmaceutical radium-223 dichloride (radium-223), have provided clinicians with a greater choice of treatments...
May 3, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29787376/symptom-assessment-to-guide-treatment-selection-and-determine-progression-in-metastatic-castration-resistant-prostate-cancer-expert-opinion-and-review-of-the-evidence
#5
REVIEW
Fred Saad, Frédéric Pouliot, Brita Danielson, Charles Catton, Anil Kapoor
Multiple new agents to treat metastatic castration-resistant prostate cancer (mCRPC) have become available in recent years; however, the appropriate timing and sequencing of these agents have yet to be elucidated. Until accurate biomarkers become available to allow more focused therapeutic targeting for this population, treatment selection for men with mCRPC will continue to be driven largely by close assessment of patient-related factors and symptoms. Pain, as the predominant symptom of mCRPC, is often the focus when assessing progression and the need for a change in treatment...
May 14, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29786792/protocols-for-the-study-of-taxanes-chemosensitivity-in-prostate-cancer
#6
M Luz Flores, Carmen Sáez
Prostate cancer is major cause of cancer-related death among men in Western countries. Locally advanced prostate cancers are treated with castration therapy, which is initially effective, but after months the disease progresses to a hormone-refractory state whose treatment is chemotherapy based on taxanes. Although taxanes improve the survival of patients with castration-resistant prostate cancers, these patients often develop chemotherapy resistance, and new therapeutic strategies are necessary. Taxanes exert their action through interaction with β-tubulin which triggers cell cycle arrest in mitosis and the subsequent induction of the intrinsic apoptotic pathway...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29785515/prostate-specific-antigen-flare-induced-by-223-racl-2-in-patients-with-metastatic-castration-resistant-prostate-cancer
#7
Angelo Castello, H A Macapinlac, E Lopci, E B Santos
PURPOSE: Prostate-specific antigen (PSA) flare is a well-known phenomenon in patients with prostate cancer, but its impact during radium-223 dichloride (223 RaCl2 ) therapy is still unclear. This radioisotope has shown to improve overall survival in metastatic castration-resistant prostate cancer (mCRPC). We sought to evaluate the impact of PSA flare on survival and its relation with metabolic parameters on 18 F-labeled sodium fluoride PET/CT. METHODS: We conducted a retrospective study of 168 patients with mCRPC (median age 69; median PSA 29...
May 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29785122/aloperine-executes-antitumor-effects-through-the-induction-of-apoptosis-and-cell-cycle-arrest-in-prostate-cancer-in-vitro-and-in-vivo
#8
Zhixin Ling, Han Guan, Zonghao You, Can Wang, Ling Hu, Lei Zhang, Yiduo Wang, Shuqiu Chen, Bin Xu, Ming Chen
Background: Prostate cancer (PCa) is one of the most common malignant diseases among male patients. Although androgen deprivation therapy remains the main treatment for PCa, most patients would inevitably progress to castration-resistant PCa, which is the main cause of cancer-related deaths. Thus, novel antitumor agents are urgently needed. Recent studies demonstrated that aloperine (ALO) as a natural alkaloid showed antitumor effects in other cancer types. However, the biological function and underlying mechanisms of ALO in PCa have not been investigated...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29781343/issues-and-promises-of-bevacizumab-in-prostate-cancer-treatment
#9
Vittore Cereda, Vincenzo Formica, Mario Roselli
There is general agreement that increased angiogenesis is an important factor in determining prostate cancer development and prognosis. Vascular Endothelial Growth Factor (VEGF) is thought to play a primary role in the molecular events that lead to prostate cancer progression, from androgen-dependency to castration-resistance until dissemination to the skeleton. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has exhibited clinical activity in different cancer types. Areas covered: In this review we summarize the data of clinical trials, investigating the effects of bevacizumab in prostate cancer patients...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29780751/metastatic-castration-resistant-prostate-cancer-and-the-challenge-of-a-patient-with-chronic-kidney-disease-in-hemodialysis
#10
Joana Simões, Isabel Augusto, Sara Meireles, Lurdes Vendeira, Carlos Silva
At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223...
April 2018: Autopsy & Case Reports
https://www.readbyqxmd.com/read/29778323/is-there-a-flare-phenomenon-on-bone-scintigraphy-in-men-with-advanced-prostate-cancer-treated-with-radium-223
#11
Gesa Isensee, Anne Péporté, Joachim Müller, Sabine Schmid, Silke Gillessen, Aurelius Omlin
INTRODUCTION: Radium-223 is an approved survival-prolonging treatment option in men with castration-resistant prostate cancer (mCRPC) and bone metastases. In the registration trial (ALSYMPCA), no regular imaging was mandated. We aimed to analyze men with metastatic mCRPC treated with radium-223 who had bone scintigraphy for staging and treatment monitoring. PATIENTS AND METHODS: Retrospective chart review was performed of mCRPC patients who received 6 cycles of radium-223 and who underwent bone scintigraphy before start of radium-223 and after 3 and 6 cycles of treatment...
April 23, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29777112/micrornas-as-potential-therapeutics-to-enhance-chemosensitivity-in-advanced-prostate-cancer
#12
Hui-Ming Lin, Iva Nikolic, Jessica Yang, Lesley Castillo, Niantao Deng, Chia-Ling Chan, Nicole K Yeung, Eoin Dodson, Benjamin Elsworth, Calan Spielman, Brian Y Lee, Zoe Boyer, Kaylene J Simpson, Roger J Daly, Lisa G Horvath, Alexander Swarbrick
Docetaxel and cabazitaxel are taxane chemotherapy treatments for metastatic castration-resistant prostate cancer (CRPC). However, therapeutic resistance remains a major issue. MicroRNAs are short non-coding RNAs that can silence multiple genes, regulating several signalling pathways simultaneously. Therefore, synthetic microRNAs may have therapeutic potential in CRPC by regulating genes involved in taxane response and minimise compensatory mechanisms that cause taxane resistance. To identify microRNAs that can improve the efficacy of taxanes in CRPC, we performed a genome-wide screen of 1280 microRNAs in the CRPC cell lines PC3 and DU145 in combination with docetaxel or cabazitaxel treatment...
May 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29776913/-177-lu-psma-617-has-activity-in-castration-resistant-prostate-cancer
#13
(no author information available yet)
Radionuclide treatment with [177 Lu]-PSMA-617 (LuPSMA) reduced PSA levels by ≥50% in 57% of patients.
May 18, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29772621/-a-case-of-choroidal-and-brain-metastases-from-castration-resistant-prostate-cancer
#14
Shuko Yoneyama, Takahiko Watanabe, Tatsuaki Onuki, Kazuro Yabuki, Kotaro Suzuki
Choroidal and central nervous system metastases from prostate cancer are extremely rare. We report a case of choroidal and brain metastases from castration-resistant prostate cancer (CRPC). A 75-year-old male patient with metastatic CRPC presented with a 1-week history of a decrease in visual acuity in his left eye. An ophthalmoscopic examination revealed a choroidal tumor, 4 disc diameters across with serious retinal detachment. He was diagnosed with metastatic choroidal tumor from examination and patient's background...
April 2018: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29772102/novel-nomograms-for-castration-resistant-prostate-cancer-and-survival-outcome-in-patients-with-de-novo-bone-metastatic-prostate-cancer
#15
Jinge Zhao, Guangxi Sun, Banghua Liao, Xingming Zhang, Cameron M Armstrong, Xiaoxue Yin, Jiandong Liu, Junru Chen, Yaojing Yang, Peng Zhao, Qidun Tang, Zhenghao Wang, Zhibin Chen, Xiong Li, Qiang Wei, Xiang Li, Ni Chen, Allen C Gao, Pengfei Shen, Hao Zeng
OBJECTIVES: To develop nomograms predicting the incidence of castration resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (mPCa). MATERIALS AND METHODS: Data from 449 de novo mPCa patients were retrospectively analyzed. Patients were randomly divided into the training (n=314, 70%) and validation cohort (n=135, 30%). Predictive factors were selected by Cox-proportional model and further used for building predictive models...
May 17, 2018: BJU International
https://www.readbyqxmd.com/read/29765513/20-s-protopanaxadiol-regio-selectively-targets-androgen-receptor-anticancer-effects-in-castration-resistant-prostate-tumors
#16
Mohamed Ben-Eltriki, Subrata Deb, Mohamed Hassona, Gray Meckling, Ladan Fazli, Mei Yieng Chin, Nada Lallous, Takeshi Yamazaki, William Jia, Paul S Rennie, Artem Cherkasov, Emma S Tomlinson Guns
We have explored the effects of 20(S)-protopanaxadiol (aPPD), a naturally derived ginsenoside, against androgen receptor (AR) positive castration resistant prostate cancer (CRPC) xenograft tumors and have examined its interactions with AR. In silico docking studies for aPPD binding to AR, alongside transactivation bioassays and in vivo efficacy studies were carried out in the castration-resistant C4-2 xenograft model. Immunohistochemical (IHC) and Western blot analyses followed by evaluation of AR, apoptotic, cell cycle and proliferative markers in excised tumors was performed...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29765147/systemic-treatments-for-high-risk-localized-prostate-cancer
#17
REVIEW
Géraldine Pignot, Denis Maillet, Emmanuel Gross, Philippe Barthelemy, Jean-Baptiste Beauval, Friederike Constans-Schlurmann, Yohann Loriot, Guillaume Ploussard, Paul Sargos, Marc-Olivier Timsit, Sébastien Vincendeau, Gilles Pasticier, Delphine Borchiellini
The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes...
May 15, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29764892/intense-exercise-for-survival-among-men-with-metastatic-castrate-resistant-prostate-cancer-interval-gap4-a-multicentre-randomised-controlled-phase-iii-study-protocol
#18
Robert U Newton, Stacey A Kenfield, Nicolas H Hart, June M Chan, Kerry S Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A Galvão, Charles J Ryan, Fred Saad
INTRODUCTION: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS AND ANALYSIS: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC)...
May 14, 2018: BMJ Open
https://www.readbyqxmd.com/read/29764864/targeting-the-hsp40-hsp70-chaperone-axis-as-a-novel-strategy-to-treat-castration-resistant-prostate-cancer
#19
Michael A Moses, Yeong Sang Kim, Genesis M Rivera-Marquez, Nobu Oshima, Matthew J Watson, Kristin Beebe, Catherine Wells, Sunmin Lee, Abbey D Zuehlke, Hao Shao, William E Bingman, Vineet Kumar, Sanjay Malhotra, Nancy L Weigel, Jason E Gestwicki, Jane Trepel, Leonard M Neckers
Castration-resistant prostate cancer (CRPC) is characterized by reactivation of androgen receptor (AR) signaling in part by elevated expression of AR splice variants (ARv) including ARv7, a constitutively active, ligand binding domain (LBD)-deficient variant whose expression has been correlated with therapeutic resistance and poor prognosis. In a screen to identify small molecule dual inhibitors of both androgen-dependent and androgen-independent AR gene signatures, we identified the chalcone C86. Binding studies using purified proteins and CRPC cell lysates revealed C86 to interact with heat shock protein 40 (Hsp40)...
May 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29762619/isolation-and-genome-sequencing-of-individual-circulating-tumor-cells-using-hydrogel-encapsulation-and-laser-capture-microdissection
#20
Emily S Park, Justin P Yan, Richard A Ang, Jeong Hyun Lee, Xiaoyan Deng, Simon P Duffy, Kevin Beja, Matti Annala, Peter C Black, Kim N Chi, Alexander W Wyatt, Hongshen Ma
Circulating tumor cells (CTCs) are malignant cells released into the bloodstream with the potential to form metastases in secondary sites. These cells, acquired non-invasively, represent a sample of highly relevant tumor tissue that is an alternative to difficult and low-yield tumor biopsies. In recent years, there has been growing interest in genomic profiling of CTCs to enable longitudinal monitoring of the tumor's adaptive response to therapy. However, due to their extreme rarity, genotyping CTCs has proved challenging...
May 15, 2018: Lab on a Chip
keyword
keyword
45028
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"